BRD2 and myeloid sarcoma: We expected (i) changes of central NAT availability in immunotherapy-naïve MS patients compared to healthy controls (HC) and explored (ii) whether there is an association of NAT with physical disability, time since manifestation and psychometric measures of fatigue and depressive symptoms in MS patients.